Tempus AI launched the ArteraAI Prostate Test for patients with metastatic hormone-sensitive prostate cancer. This release marks the first time Tempus has integrated an externally developed digital pathology algorithm into its platform.
The AI-powered tool analyzes biopsy images and clinical data to predict prostate cancer-specific mortality. Clinicians use these insights to personalize the intensity of patient therapy.
Physicians can order the test as an add-on to existing Tempus solid tumor offerings. The system combines genomic sequencing results with pathology-based AI insights for a comprehensive assessment.
The test targets approximately 25,000 patients newly diagnosed with this specific prostate cancer in the U.S. annually.